The OJC S4E6: HIPEC Hits a Wall, Beyond Curative vs Palliative + ctDNA After Metastasectomy
The Oncology PodcastShow Notes
Send us Fan Mail Negative trials matter. In this episode, the Oncology Journal Club team discuss research that challenges established practice, alongside thought-provoking papers exploring how we communicate treatment goals in the era of immunotherapy and precision oncology. Professor Chris Jackson reviews the PERISCOPE II trial, showing that adding gastrectomy, cytoreductive surgery and HIPEC to systemic therapy does not improve survival for patients with gastric cancer and limited peritonea...
More from The Oncology Podcast
Send us Fan Mail In this episode of The Oncology Journal Club, we take a wide-ranging look at the latest oncology research, exploring treatment strategies for deficient mismatch repair (dMMR) metastatic colorectal cancer, new evidence on organ preservation in early rectal cancer, updated ASCO recommendations for advanced non-small cell lung cancer and the potential impact of proton pump inhibitors on immunotherapy outcomes. The team also tackle a range of Quick Bites, including the impl...
Send us Fan Mail Hosted by Associate Professor Jenny Liu and Rachael Babin | Proudly Produced by The Oncology Network Welcome to Episode 2 of Making Cancer Care Smarter, brought to you by The Oncology Network. Hosted by Rachael Babin and Associate Professor Jenny Liu, this episode features Eric Yeung from CanRevive. What does person-centred cancer care really look like when patients and families come from different cultural and linguistic backgrounds? We speak with Eric about the challenges C...
Send us Fan Mail In this episode, the Oncology Journal Club team take a whistle-stop tour through some of the latest evidence in breast, colorectal, lung and thyroid cancer, with plenty to discuss around AI pathology, access to palliative care and the ever-changing world of ASCO Guidelines. We kick things off with a lively deep dive into SERENA-6 and the idea of switching treatment when an ESR1 mutation emerges — before the cancer has actually progressed — in first-line treatment of hormone r...
Send us Fan Mail The September changes to Australia's PBS will have a wide and lasting impact on the oncology treatment landscape. Rachael Babin from the Oncology Network sits down with Professor Craig Underhill to translate the latest Australian Pharmaceutical Benefits Scheme (PBS) oncology and haematology listings into what clinicians actually need: who’s eligible, what the key trials show and what to watch for once the script is written. This month we unpack three significant PBS dev...
Send us Fan Mail PBS listings can radically reshape practice and the August changes are all about precision. Rachael Babin from the Oncology Network sits down with Professor Craig Underhill to translate the latest Australian Pharmaceutical Benefits Scheme (PBS) oncology and haematology listings into what clinicians actually need: who’s eligible, what the key trials show and what to watch for once the script is written. We start with vorasidenib, newly listed for IDH mutant astrocytoma...